Oxford Drug Design

Oxford Drug Design Limited is a biotechnology company located in Oxford, UK, with proprietary computational and machine learning platforms. Led by CEO Alan D. Roth, it designs and develops small-molecule anticancer drugs based on differentiated dual-core capabilities. Its validated platform combines groundbreaking artificial intelligence and machine learning approaches with deep expertise in aminoacyl-tRNA synthetases, accelerating the discovery and development of oncology therapies with novel mechanisms of action.